Activist investor takes stake in BioMarin as drug maker switches out CEOs

Incoming President and CEO Alexander Hardy will get a $900,000 signing bonus after leaving Genentech’s top job and could receive $20 million or more in stock over time; outgoing boss Jean-Jacques Bienaimé could land nearly $1.4 million as a company consultant.
Click here to view original post